Connexion
S'inscrire
Réinitialiser le mot de passe
Publier & Distribuer
Solutions d'édition
Solutions de distribution
Thèmes
Architecture et design
Arts
Business et économie
Chimie
Chimie industrielle
Droit
Géosciences
Histoire
Informatique
Ingénierie
Intérêt général
Linguistique et sémiotique
Littérature
Mathématiques
Musique
Médecine
Pharmacie
Philosophie
Physique
Sciences bibliothécaires et de l'information, études du livre
Sciences des matériaux
Sciences du vivant
Sciences sociales
Sport et loisirs
Théologie et religion
Études classiques et du Proche-Orient ancient
Études culturelles
Études juives
Publications
Journaux
Livres
Comptes-rendus
Éditeurs
Blog
Contact
Chercher
EUR
USD
GBP
Français
English
Deutsch
Polski
Español
Français
Italiano
Panier
Home
Journaux
The EuroBiotech Journal
Édition 3 (2019): Edition 1 (January 2019)
Accès libre
Low-frequency ultrasound can drive the transport of nanoparticles and molecules in polymer gels for biotechnology applications
Donald K. Martin
Donald K. Martin
| 25 janv. 2019
The EuroBiotech Journal
Édition 3 (2019): Edition 1 (January 2019)
À propos de cet article
Article précédent
Article suivant
Résumé
Article
Figures et tableaux
Références
Auteurs
Articles dans cette édition
Aperçu
PDF
Citez
Partagez
Article Category:
Research Article
Publié en ligne:
25 janv. 2019
Pages:
1 - 9
DOI:
https://doi.org/10.2478/ebtj-2019-0001
Mots clés
Gold nanoparticles
,
agarose gel
,
drug delivery
,
low-frequency ultrasound
© 2019 Donald K. Martin, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Figure 1
Apparatus used to measure the transport of tracer gold nanoparticles that as stimulated by low-frequency ultrasound. The block diagram of the components is drawn in panel A, and the actual gels+transducer is shown in panel B. The light path is illustrated with the dotted line, and was aimed to pass through the “receiver-gel” at a distance marked x below the interface with the “tracer-gel”. The numbers in panels A and B refer to the same components. (1=ultrasonic transducer, 2=”tracer-gel”, 3=”receiver-gel”, 4=glass microscope slide, 5=signal generator, 6=HeNe laser, 7=photodiode, 8=computer).
Figure 2
Measurement of transmittance of the “receiver-gel” at x=1mm depth from the interface with the “tracer-gel” that contained the gold nanoparticles.
Figure 3
Measurement of transmittance of the “receiver-gel” at x=2mm depth from the interface with the “tracer-gel” that contained the gold nanoparticles.
Figure 4
SEM image of the “receiver-gel” from the diffusion experiment shown in Fig. 1. For the purposes of the SEM imaging the gel was dehydrated. The electron-dense particles (light grey colour) are at the surface of the dehydrated gel. The arrows point to particles that are most likely to be gold, with the alrger particles most likely to be crystals of chemicals used in the buffer solutions (see text for explanation).
Figure 5
SEM/EDS analysis of the smaller particles observed in the dehydrated gels shown in Figure 4. The EDS analysis in panel B is of the particle imaged by SEM in panel A. The analysis shows that the composition of the particle in panel A is gold.
Figure 6
Measurement of transmittance of the “receiver-gel” at x=1mm depth from the interface with the “tracer-gel” that did not contain any gold nanoparticles.
Figure 7A
Masson-stained section of a posterior area of a rabbit eye into which bevacizumab was delivered from the “tracer-gel”. The sclera is stained bright blue and the retina, epithelia and muscle stained crimson. The retina and choroid have separated from the sclera.
Figure 7B
Masson-stained section of the limbal region of a rabbit eye into which bevacizumab was delivered from the “tracer-gel”. The sclera and cornea are stained bright blue and the retina, epithelia and muscle stained crimson. The retina and choroid have separated from the sclera.
Figure 8
Sections of the retina and sclera around the posterior pole of the rabbit eyes. In all panels the retina is marked “ret” and the sclera is marked “scl”. (A) bevacizumab, free in gel (rabbit 1, left eye), (B) bevacizumab, in liposomes (rabbit 1, right eye), (C) negative control (rabbit 2, left eye), (D) ranibizumab, free in gel (rabbit 2, right eye), (E) verteporfin, direct injection into vitreous chamber (rabbit 3, left eye), (F) verteporfin, in liposomes (rabbit 3, right eye).
Aperçu